NanoString also beat analyst estimates on the top and bottom lines, and upped its revenue guidance for the year based primarily on collaboration revenues.
Illumina received more orders than expected for NovaSeq in Q2 and sees a big opportunity in the consumer genomics market for its array business and Helix.
The study will combine cognitive assessments with genetic data and survey responses to gain insights into the causes of these two mental health conditions.
A pair of new studies evaluated whole-exome sequencing and other genetic tests in children with epilepsy and in other undiagnosed monogenic disease cases.
With discovery and replication meta-analyses on data for more than 100,000 individuals, researchers identified variants that influence lean mass near five genes.
They demonstrated the applicability of the Simoa platform for nucleic acid detection, and miRNA detection in particular, as Quanterix prepares to launch a new system.
Using a combination of genome-wide association and expression quantitative trait loci approaches, investigators uncovered shared and population-specific thyroid cancer risk loci.
The company has not published on its technology, but claims proprietary materials and methods allow it to detect targets in unprocessed biological samples with sub-femtomolar sensitivity.
A small study of prostate cancers from African American and European American men uncovered ancestry-associated splicing with apparent ties to tumor aggressiveness and resistance.
Using array-based miRNA profiles for individuals treated for prostate cancer, researchers identified 37 miRNA with differential expression in cases with recurrence.
Even in schizophrenia cases lacking intellectual disability, investigators found that rare mutations in genes normally resistant to loss-of-function changes were enriched.
Suspicious variants were uncovered through analyses of pediatric cancer survivors from the St. Jude Lifetime Cohort Study and Childhood Cancer Survivor Study.
The company will sell 3 million shares with RW Baird as the sole underwriter of the offering, with a 30-day option to purchase an additional 450,000 shares.
